DGAP-News: HAEMATO AG

DGAP-News: HAEMATO AG: 2015: Preliminary IFRS results, sales increase of 13 % to EUR 229.7 million, operating result (EBIT) of EUR 8.2 million at the level of the previous year; investments in the development of the business area of medical devices

DGAP-News: HAEMATO AG / Key word(s): Preliminary Results/Development of Sales HAEMATO AG: 2015: Preliminary IFRS results, sales increase of 13 % to EUR 229.7 million, operating result (EBIT) of EUR 8.2 million at the level of the previous year; investments in the development of the business area of medical devices

16.03.2016 / 08:00 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Corporate News of HAEMATO AG: 2015: Preliminary IFRS results, sales increase of 13 % to EUR 229.7 million, operating result (EBIT) of EUR 8.2 million at the level of the previous year; investments in the development of the business area of medical devices

In the financial year 2015 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 229.7 million (prior year: EUR 202.7 million) and an operating result (EBIT) of EUR 8.2 million (prior year: EUR 8.2 million).

"In the fourth quarter of 2015 the HAEMATO Group has exceeded sales of the prior-year period by 46 %. Thus, growth improved slightly over the 43 % increase in the third quarter compared to the prior-year period. We are investing in the development of the business area of medical devices under the brand name HAEMATO MED. The investments will pay off from the second half of 2016. In the light of a favourable development of the HAEMATO PHARM business in the first ten weeks of the financial year 2016, we are confident concerning an increase in sales and profit for the whole year 2016", says Dr. Christian Pahl, Member of the Management Board of HAEMATO AG.

About HAEMATO:

HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases.

HAEMATO AG is listed in the Entry Standard (Open Market) on the Frankfurt Stock Exchange. Key figures for the share of HAEMATO AG: Subscribed capital: EUR 20,778,898 Listed shares: ordinary shares ISIN: DE000619070 WKN: 619070 Stock symbol: HAE

Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de

---------------------------------------------------------------------------

16.03.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

445247 16.03.2016